Endothelial cell-activating antibodies in COVID-19.
Hui ShiYu ZuoSherwin NavazAlyssa HarbaughClaire HoyAlex A GandhiGautam SuleSrilakshmi YalavarthiKelsey GockmanJacqueline A MadisonJintao WangMelanie ZuoYue ShiMichael D MaileChristian LoodYogendra KanthiPublished in: medRxiv : the preprint server for health sciences (2021)
What is already known about this subject?: Patients with COVID-19 are at high risk for fibrin-based occlusion of vascular beds of all sizes.Endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm.What does this study add?: The presence of circulating antiphospholipid antibodies may be a predictor of the ability of a patient’s total antibody profile to activate endothelial cells.Purified COVID-19 IgG with high levels of anticardiolipin and anti-PS/PT activity trigger a pro-adhesive phenotype in endothelial cells.How might this impact on clinical practice or future developments?: Patients might be screened for antiphospholipid antibodies to evaluate their risk of having an antibody profile likely to activate endothelial cells.Patients with high antiphospholipid antibody titers might benefit from treatments used in traditional cases of severe APS such as therapeutic anticoagulation, corticosteroids, and plasmapheresis.
Keyphrases
- endothelial cells
- coronavirus disease
- sars cov
- systemic lupus erythematosus
- high glucose
- end stage renal disease
- clinical practice
- vascular endothelial growth factor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- atrial fibrillation
- peritoneal dialysis
- signaling pathway
- case report
- respiratory syndrome coronavirus
- prognostic factors
- early onset
- venous thromboembolism
- current status
- finite element